Comparing Utah Medical Products (NASDAQ:UTMD) and Neuronetics (NASDAQ:STIM)

Utah Medical Products (NASDAQ:UTMD – Get Free Report) and Neuronetics (NASDAQ:STIM – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, earnings and dividends.

Insider & Institutional Ownership

69.6% of Utah Medical Products shares are held by institutional investors. Comparatively, 53.6% of Neuronetics shares are held by institutional investors. 8.0% of Utah Medical Products shares are held by company insiders. Comparatively, 8.4% of Neuronetics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent recommendations for Utah Medical Products and Neuronetics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Utah Medical Products 0 1 0 0 2.00
Neuronetics 1 0 5 0 2.67

Neuronetics has a consensus target price of $5.00, suggesting a potential upside of 300.00%. Given Neuronetics’ stronger consensus rating and higher possible upside, analysts plainly believe Neuronetics is more favorable than Utah Medical Products.

Risk & Volatility

Utah Medical Products has a beta of 0.38, meaning that its share price is 62% less volatile than the S&P 500. Comparatively, Neuronetics has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500.

Profitability

This table compares Utah Medical Products and Neuronetics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Utah Medical Products 30.48% 8.83% 8.59%
Neuronetics -14.45% -102.23% -16.83%

Earnings and Valuation

This table compares Utah Medical Products and Neuronetics”s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Utah Medical Products $38.52 million 5.97 $11.29 million $3.34 21.66
Neuronetics $149.16 million 0.65 -$39.00 million ($0.33) -3.79

Utah Medical Products has higher earnings, but lower revenue than Neuronetics. Neuronetics is trading at a lower price-to-earnings ratio than Utah Medical Products, indicating that it is currently the more affordable of the two stocks.

Summary

Utah Medical Products beats Neuronetics on 8 of the 14 factors compared between the two stocks.

About Utah Medical Products

(Get Free Report)

Utah Medical Products, Inc. develops, manufactures and markets medical devices, with a focus on disposable products used in obstetrics, gynecology and neonatal care. Its offerings include devices and accessories for fetal monitoring, labor and delivery, newborn care and related clinical procedures. Founded in 1978 and headquartered in Midvale, Utah, the company also serves other areas of healthcare, including surgery and emergency care. Its products reach customers in the United States and international markets through a combination of direct sales and distribution channels.

About Neuronetics

(Get Free Report)

Neuronetics, Inc. is a medical technology company that develops and commercializes noninvasive treatments for certain mental health conditions. Its flagship product is the NeuroStar Advanced Therapy System, which uses transcranial magnetic stimulation to deliver targeted magnetic pulses to areas of the brain. NeuroStar is FDA-cleared for treating major depressive disorder in adults who have not achieved satisfactory improvement with antidepressant medication. The company also provides treatment-related services and support for clinicians and patients.

Receive News & Ratings for Utah Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Utah Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.